Literature DB >> 31941258

[Guidelines for the prevention and treatment of hepatitis C (2019 version)].

.   

Abstract

In order to standardize and update the prevention, diagnosis and antiviral therapy of hepatitis C and to achieve the World Health Organization's goal of eliminating viral hepatitis as a public health threat by 2030, Chinese Medical Association, the Chinese Society of Hepatology, and the Society of Infectious Diseases organized relevant native experts in 2019 to revise the guideline for the prevention and treatment of hepatitis C (2019 version) based on the basic, clinical and prophylactic research progress of hepatitis C infection at home and abroad, combined with the present actual situation of our country, so as to provide an important basis for the prevention, diagnosis and treatment of hepatitis C.

Entities:  

Keywords:  Direct antiviral agent; Guideline; Hepatitis C; Prevention; Treatment

Year:  2019        PMID： 31941258     DOI： 10.3760/cma.j.issn.1007-3418.2019.12.008

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN： 1007-3418


  13 in total

1.  Efficacy and safety of elbasvir/grazoprevir treatment for Chinese patients with hepatitis C virus genotype 1b: a retrospective study.

Authors:  Juan Li; Guangming Li; Juanxia Wang; Rui Zhao; Jingjing He; Liang Wang; Lingyi Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

2.  Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis.

Authors:  Zepei Feng; Jinwei Zhang; Weilong Tan; Chunhui Wang; Qiong Chen; Chao Shen; Haozhi Fan; Yun Zhang; Peng Huang; Ming Yue
Journal:  Front Med (Lausanne)       Date:  2022-05-18

Review 3.  Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives.

Authors:  Zeyu Zhao; Meijie Chu; Yichao Guo; Shiting Yang; Guzainuer Abudurusuli; Roger Frutos; Tianmu Chen
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

Review 4.  Chinese guidelines on the management of liver cirrhosis (abbreviated version).

Authors:  Xiao-Yuan Xu; Hui-Guo Ding; Wen-Gang Li; Jing-Hang Xu; Ying Han; Ji-Dong Jia; Lai Wei; Zhong-Ping Duan; En-Qiang Ling-Hu; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2020-12-07       Impact factor: 5.742

5.  The impact of COVID-19 on the cascade of care of HCV in the US and China.

Authors:  Yee Hui Yeo; Xu Gao; Jian Wang; Qingyu Li; Xingyang Su; Yu Geng; Rui Huang; Chao Wu; Fanpu Ji; Vinay Sundaram; Mazen Noureddin; Maria Buti; Walid S Ayoub
Journal:  Ann Hepatol       Date:  2022-02-19       Impact factor: 3.388

6.  Expression and Clinical Values of Serum miR-155 and miR-224 in Chinese Patients with HCV Infection.

Authors:  Xiaochun Jin; Ying Zhang; Hui Wang; Youtao Zhang
Journal:  Int J Gen Med       Date:  2022-02-10

7.  Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.

Authors:  Guolan Wu; Huili Zhou; Jing Wu; Duo Lv; Lihua Wu; You Zhai; Meihua Lin; Jingzi J Wu; Jianzhong Shentu
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

8.  Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis.

Authors:  Huan Xia; Yaping Zhang; Silvere D Zaongo; Jing Liang; Xiaowen Gong; Yue Hu; Ping Ma; Fengmei Wang
Journal:  Ann Transl Med       Date:  2021-05

9.  Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.

Authors:  Xia Wei; Jingyu Zhao; Li Yang
Journal:  BMJ Glob Health       Date:  2020-11

Review 10.  Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China.

Authors:  Xiaozhong Wang; Lai Wei
Journal:  J Clin Transl Hepatol       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.